肠道菌群在危重症患者中的核心与生物动力学作用
本文为叙述性综述,概述肠道菌群的正常组成与功能、导致菌群失调的机制、其在重症监护环境中的后果,并提出肠-器官轴概念。危重症患者可能存在肠道菌群失调,表现为促进健康的共生肠道细菌(如厚壁菌门或拟杆菌门)严重减少、潜在致病细菌(如变形菌门)增加。危重症患者中发生的许多因素(如药物或营养模式改变)促进菌群失调。菌群失调导致肠道完整性和短链脂肪酸、氧化三甲胺等代谢物产生改变,并与其他器官相互作用,可能影响危重症的进展。
要点
- 危重症患者可能存在肠道菌群失调,表现为促进健康的共生肠道细菌(如厚壁菌门或拟杆菌门)严重减少、潜在致病细菌(如变形菌门)增加。
- 危重症患者中发生的许多因素(如药物或营养模式改变)促进菌群失调。
- 菌群失调导致肠道完整性和短链脂肪酸、氧化三甲胺等代谢物产生改变。
- 肠道菌群及其改变与其他器官相互作用,即肠-器官轴概念;菌群失调会影响其他器官,并可能影响危重症的进展。
- 当前知识仅是待发现内容的一小部分,肠道菌群及其与各器官相互作用的精确作用和贡献是激烈而富有挑战性的研究领域。
适用人群与场景
- 危重症患者,尤其关注多器官衰竭的重症监护场景。
研究设计与关键结果
- 本文为叙述性综述,提供肠道菌群正常组成、功能、导致菌群失调的机制、其在重症监护环境中的后果以及肠-器官轴概念的概述。
- 危重症患者可能存在肠道菌群失调,表现为促进健康的共生肠道细菌(如厚壁菌门或拟杆菌门)严重减少、潜在致病细菌(如变形菌门)增加。
- 危重症患者中发生的许多因素(如药物或营养模式改变)促进菌群失调。
- 菌群失调导致肠道完整性和短链脂肪酸、氧化三甲胺等代谢物产生改变。
- 肠道菌群及其改变与其他器官相互作用,即肠-器官轴概念;菌群失调会影响其他器官,并可能影响危重症的进展。
证据类型、等级与局限
- 证据类型:叙述性综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,肠道菌群及其与各器官相互作用的精确作用和贡献是激烈而富有挑战性的研究领域,为疾病预防、管理和治疗提供了令人兴奋的机会,尤其在多器官衰竭常为核心的重症监护中。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Gut microbiota plays an essential role in health and disease. It is constantly evolving and in permanent communication with its host. The gut microbiota is increasingly seen as an organ, and its failure, reflected by dysbiosis, is seen as an organ failure associated with poor outcomes. Critically ill patients may have an altered gut microbiota, namely dysbiosis, with a severe reduction in "health-promoting" commensal intestinal bacteria (such as Firmicutes or Bacteroidetes) and an increase in potentially pathogenic bacteria (e.g. Proteobacteria). Many factors that occur in critically ill patients favour dysbiosis, such as medications or changes in nutrition patterns. Dysbiosis leads to several important effects, including changes in gut integrity and in the production of metabolites such as short-chain fatty acids and trimethylamine N-oxide. There is increasing evidence that gut microbiota and its alteration interact with other organs, highlighting the concept of the gut-organ axis. Thus, dysbiosis will affect other organs and could have an impact on the progression of critical diseases. Current knowledge is only a small part of what remains to be discovered. The precise role and contribution of the gut microbiota and its interactions with various organs is an intense and challenging research area that offers exciting opportunities for disease prevention, management and therapy, particularly in critical care where multi-organ failure is often the focus. This narrative review provides an overview of the normal composition of the gut microbiota, its functions, the mechanisms leading to dysbiosis, its consequences in an intensive care setting, and highlights the concept of the gut-organ axis.
参考来源
- Wozniak H, Beckmann TS, Fröhlich L, et al. The central and biodynamic role of gut microbiota in critically ill patients. Crit Care. 2022. PMID: 35982499. doi:10.1186/s13054-022-04127-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。